Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility
Kenneth Blum1, Mary Hauser2, James Fratantonio3
1Department of Psychiatry, McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Abstract:
The Brain Reward Cascade (BRC) is an interaction of neurotransmitters and their respective genes to control the amount of dopamine released within the brain. Any variations within this pathway, whether genetic or environmental (epigenetic), may result in addictive behaviors as well as altered pain tolerance. While there are many studies claiming a genetic association with addiction and other behavioral infractions, defined as Reward Deficiency Syndrome (RDS), not all are scientifically accurate and in some case just wrong. Albeit our bias, we discuss herein the facts and fictions behind molecular genetic testing in RDS (including pain and addiction) and the significance behind the development of the Genetic Addiction Risk Score (GARSPREDX™), the first test to accurately predict one's genetic risk for RDS.
More Related Videos
Related Concept Videos
Drug Abuse and Addiction: Pharmacological Phenomena
Analgesia and Pain Management
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Pharmacogenomics: Identification of New Drug Targets
Drug Dependence


